Form 4: Bicara Therapeutics CEO Sells Shares Under 10b5-1 Plan

Bicara Therapeutics CEO Claire Mazumdar exercised stock options and subsequently sold an equal number of common shares under a pre-arranged trading plan.

Summary

• Claire Mazumdar, CEO and Director of Bicara Therapeutics Inc. (BCAX), executed a transaction on October 16, 2025.
• The transaction involved the exercise of 24,103 stock options at an exercise price of $3.7898 per share.
• Immediately following the option exercise, 24,103 shares of common stock were sold.
• The shares were sold at a weighted average price of $18.8259, with individual sales ranging from $18.73 to $19.17.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.
• After these transactions, Claire Mazumdar directly holds 309,892 shares of common stock and 277,270 stock options.

Sentiment

Score: 5

Explanation: The transaction is a routine insider sale executed under a pre-arranged 10b5-1 plan, indicating a neutral sentiment as it's not an opportunistic sale and is likely for personal financial planning.

Positives

• The CEO realized a significant profit from the option exercise and subsequent sale, with the sale price ($18.8259) being substantially higher than the exercise price ($3.7898).
• The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned, non-opportunistic sale for personal liquidity or diversification.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived negatively by the market, potentially leading to questions about management's long-term outlook, though this is mitigated by the 10b5-1 plan.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This insider transaction report does not provide information directly related to broader industry trends or competitive landscape.

Related Party Transactions

• The reported transactions are insider dealings by the Chief Executive Officer and Director of Bicara Therapeutics Inc.

Stakeholder Impact

• Shareholders may observe the CEO's sale of shares, which, while pre-planned, could lead to minor sentiment shifts.
• Employees are not directly impacted by this specific transaction.

Next Steps

• Continued vesting of the remaining 277,270 stock options in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service.

Key Dates

Recommendation

The filing details a pre-planned insider transaction (exercise and sale) by the CEO, executed under a Rule 10b5-1 plan. Such routine transactions typically do not signal a fundamental change in company prospects and are often for personal liquidity or diversification. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide new information to alter an investment thesis.

Keywords

Bicara Therapeutics, BCAX, Insider Trading, Form 4, Stock Options, CEO, Share Sale, 10b5-1 Plan, Claire Mazumdar